XTend Medical Set to Redefine Cancer Detection With Nanotechnology (PINK:XMDC.PK)
Cancer has quickly become one of the deadliest diseases, causing well over 13% of all human deaths. Cancer rates could further increase by 50% to 15 million new cases in the year 2020, according to the World Cancer Report, the most comprehensive global examination of the disease to date. Due to this emerging need for cancer detection medical devices, new and innovative technologies are bound to step foot within the coming years, in what could potentially be one of the biggest markets of our era. Xtend Medical (PINK:XMDC) is set to partner up with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device. Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number. The merger is expected to be completed 30 to 60 days post the October 1st, 2009 press release. BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. It is an hand-held, lightweight, portable, and affordable device which has tested for 100% no-false positives, and 95.9% cancer positive . With the U.S. National Science Foundation predicting that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years — XTend, and other medical nanotechnology devices should begin to receive a lot more praise, including the likes of NASA, which has already developed a nanotechnology-based biosensor which helps detect biohazards. “If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we’ve received, the company’s market cap will be substantial,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.
About XTend Medical
XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.
The full special report on the company appears today at http://www.stockshaven.com/xtend-medical-set-to-redefine-cancer-detection-with-nanotechnology-pinkxmdc-pk/
Disclosure: Long XMDC
To feature your publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at email@example.com or visit http://www.stockshaven.com/ir_contract/ for more info
About MiV Investments Inc.
MiV Investments Inc. can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Michael Vlaicu
- President & CEO
- MiV Investments Inc.
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.